UK-based Unfabled Raises Seed Funding to Develop its Data Science Vertical

Apart from extending its platform, Unfabled intends to use the fresh funds to develop its in-house data science, a core element of its B2B offering.

Unfabled, a London, UK-based healthcare provider for women’s health and wellbeing, has secured $1.6M in Seed funding.

Founded in 2021 by Hannah Samano, Unfabled is a data-driven health platform dedicated to women’s health and wellbeing.

The funding round, which brought the total investment to $2 million, witnessed participation from several notable entities including Morgan Stanley, Exceptional Ventures, Atomico Angels, Founders Factory, Chai Ventures, Syndicate Room, and 3 Sisters Ventures.

Additionally, angel investors from the technology and healthcare sectors also contributed to the funding. These investors include Maya Ghosn (a scout for Sequoia) Shefali Roy (Apple, TrueLayer), Elaine Groenestein (first angel at Elvie), and Fiona Pathiraja

Apart from extending its platform, Unfabled intends to use the fresh funds to develop its in-house data science, a core element of its B2B offering.

Unfabled Core Offerings

Unfabled offers a platform where users answer questions about their health priorities. Based on their responses, the platform provides them with a tailored selection of products to address their specific needs. These solutions cover a range of conditions, from menstrual cramps to menopause.

Commenting on the development, Hannah Samano, founder & CEO, Unfabled, said, “Women’s health has for too long been fragmented and underserved. Unfabled has already empowered thousands of women to find effective treatments for common, yet hugely disruptive, hormonal and reproductive conditions like PMS, Polycystic Ovary Syndrome (PCOS), endometriosis, and menopause.”

Among the 33.8 million of the female population in the UK, 90% experience monthly hormonal symptoms, yet women’s health remains fragmented and underserved.

Unfabled’s core element is the B2B aspect which serves as a market intelligence platform. It provides crucial insights into consumer behavior related to women’s health.

The healthcare provider aims to empower women by providing effective treatments for common, yet disruptive, hormonal and reproductive conditions. These conditions include PMS, polycystic ovary syndrome (PCOS), endometriosis, and menopause.

“The more we understand about female health, the more laser-focused we can become on improving it,” CEO Samano added.

Reportedly, over 300,000 people are using Unfabled to discover effective treatments for various conditions, including menstrual cramps, pregnancy, and menopause.

Recent Advancements in Women's Health

Last month, Hyderabad-based Dr Reddy's Laboratories acquired US-based MenoLabs. The acquisition deal is a part of Dr Reddy's strategy to expand its presence in the rapidly growing women's nutritional and wellness market in the US.

The acquisition not only marks a strategic expansion for Dr Reddy's but also positions the company as a key player in women's health and wellness, aligning with the growing trend of consumers actively seeking nutritional and wellness solutions.

This move comes at a crucial time, as the demand for women's health products continues to rise, driven by an increasing awareness of holistic well-being. Dr Reddy's Laboratories aims to leverage the existing MenoLabs brand equity and customer base to strengthen its foothold in this competitive market.

Earlier, Gurugram-based health and wellness startup Shyft launched a new brand, Dash Health, focusing on improving women's health. Dash Health aims to enhance awareness, foster community support, and provide lifestyle management services tailored to various health conditions affecting women.

In the healthcare landscape, the women's health market is burgeoning. A recent market research study by Contrive Datum Insights unveiled that the global women's health market reached a valuation of $40.29 billion in 2022 and is expected to surge to $58.24 billion by 2030, exhibiting a CAGR of 4.8% from 2023 to 2030.

As women's health issues become more apparent and chronic diseases and hormonal imbalance-related disorders become more prevalent, the industry is experiencing upward growth.